Quality of life in kidney recipients: comparison of tacrolimus and cyclosporine‐microemulsion

Authors:

Abstract
Treatment of end‐stage renal disease (ESRD) is evaluated by survival, quality of life (QOL) and cost‐effectiveness. Little is known about the influence of immunosuppressive agents on global and disease‐specific QOL in kidney recipients.In winter 1997/98 (t0) as well as in winter 1998/99 (t1), all kidney recipients of our University were asked to participate in a QOL study. The psychodiagnostic approach combined a global QOL‐measure (SF‐36 Health Survey) and a disease‐specific questionnaire (ESRD‐SCLTM, Nephron 1999). Inclusion criteria for the final analysis were (a) participation in both surveys and (b) eligibility after the matching procedure: patients with tacrolimus‐based immunosuppressive regimen were matched to patients with cyclosporin‐microemulsion (CsA‐ME)‐based immunosuppressive‐regimen as to age, gender and duration of graft function. Group data were compared by performing a two‐variate (`immunosuppression', `time') analysis of variance. Both groups consisted of 63 patients. Analysis of QOL revealed statistically significant advantages for the tacrolimus treated patients concerning global (SF‐36 `Physical Component Summary') as well as disease‐specific QOL (ESRD‐SCLTM`Global Severity Index'; both p < 0.05). In detail, these results were due to statistically significant better QOL in tacrolimus treated patients as to the SF‐36 subscales `Physical Functioning' and `General Health' (p < 0.05) and the ESRD‐SCLTMsubscales `Limited Physical Capacity' (p < 0.05), `Cardial and Renal Dysfunction' (p < 0.01) and `Increased Growth of Gum and Hair' (p < 0.001). The factor `time' did not contribute statistically significant to explanation of variance.In terms of QOL in kidney recipients, tacrolimus is superior to CsA‐ME. Tacrolimus improves disease‐specific QOL and also shows slight advantages concerning global QOL compared with CsA‐ME. To record differentiated aspects of QOL in kidney recipients, the diagnostic approach should include a global QOL measure completed by a sensitive disease‐specific instrument.

This publication has 30 references indexed in Scilit: